Get started
MODERNAMODERNAMODERNA

MODERNA

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

1MRNA trade ideas

MRNA is going to dump now / where to buyMRNA is not looking too good. What we can see is a weekly bearish engulfing candle after clear rejection from the upsloping resistance line. Rejection was nasty therefore we're seeing instant follow through. You can short it now with a final target at the support which is the entry for longs too. At the support, flip bullish and take a long position. The target is at the key resistance shown on the chart. If you short now, pleace a stop loss at 219 - 220 $ Good luck
NASDAQ:MRNAShort
by vf_investment
8
3/29 Watchlist + NotesSPY - I had no real bias going into today's session other than mentioning last night that downside was more likely to come today because of the failed 2U daily created on monday. We closed slightly red after seeing a decent drop to the high 393 area, forming a weak bearish 2D. Going into wednesday (3/29), I am hoping to see some downward continuation to the 392/390 levels tomorrow to test that range. Key word is hoping. I remain neutral with my personal bias as we have no real clear direction this week still. Given that we closed very weak to the downside leads me to believe we can ultimately go either way tomorrow, but once again, playing what is in front of us I have to be looking more so to the downside. Watchlist + Bias: DIS - 2-1 Daily: Slightly Bullish MRNA - 2-1 Daily: Bearish. PEP - 2-1 Daily: Bearish FDX - 3-1- Weekly: Neutral Main Watch: MRNA - Back in our main spotlight for the 2nd time this week is MRNA. There is a 2-1 daily setup that is within a bearish week with a lot of room to the downside due to a huge FVG on the daily. Looking to target Monday's low of 145.36 and the 50% retrace point of the original FVG at 144.72. Will only play downside and not upside if markets pump tomorrow Also heavily watching FDX still as the 3-1 weekly has not broken out yet. Hourly chart stuck in a flat channel currently just consolidating. Yesterdays Main Watch: NVDA - (Status:) Winner (Personally Enter?) No I mentioned we had downside targets and that I wanted to play with markets momentum. I missed entry due to being in class and not being able to trade, but I saw how it played out. Broke short entry level in the first few minutes of market open and dumped past our 260 target to the mid 258 level. Cons ran a little over 75% from entry and realistically I would have caught the full move due to the dump being so consistent and strong before reversing. Watchlist Stats For The Week: 2/2 On Spy Predictions 2/2 On Main Watch Plays Top Winner: NVDA (75%+) Personal Stats: 3/5 for the week. Overall Green/Red? Green
NASDAQ:MRNA
by Alanger17
3/22 Watchlist + NotesSPY - Once again we were bullish going into today and ended up getting that upside movement we wanted. Tomorrow is FOMC so no real prediction for tomorrows movement other than some chop leading up to the news. As far as the news goes, I am leaning more on the bullish side but quite honestly that is purely a guess. Trading light tomorrow if I take anything, and not trading after news comes out. Watchlist: MRNA - 3-1: Bullish BIDU - 2-1: Neutral Main Watch: MRNA - Nothing special about this setup other than it being a 3-1 daily setup and seeing that it has more room to the upside to test a daily FVG around 157.70 Top winner from yesterdays watchlist: GOOG - 2-1 daily broke to the upside and had a gorgeous uptrend day. Calls ran just under 240% from where the long entry (yesterdays high) was
NASDAQ:MRNA
by Alanger17
$MRNA What Up$MRNA started playing this since it was in the low $20s and then got rid of it at the start of this year. And IMO this is headed under $100. It will get a kick start when the next Pandemic happens and WHO rules lockdowns across the world. Regardless of the hype, I don't see any reason to take a position in this ticker. The only outcome is, EXIT for me :) Although it does have a promising technology but it will not be able to generate the kind of revenue it did with the Pandemic vax
NASDAQ:MRNAShort
by VIN786
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by DivergenceSeeker
3
Moderna (MRNA) ... Time for a shot in the Arm ?Moderna (MNRA). This is a potential long trade if it reaches my area of interest in my PRZ (price reversal zone). A nicely formed ABCD formation together with a Harmonic Crab / Alternate Bat (depending where X starts), come together in the mid to low $160s. (This also happens to come full circle to the recent December 2022 low.) This together with positive momentum hopefully sets up one or both of the targets objectives. I wouldn't chase this and beware of broader markets. Earnings are expected Feb. 23rd at $4.70. As always DYODD. I will monitor S,
NASDAQ:MRNA
by Steve666